Print this page
Radiation
-
Targeted Genomic Analysis of Human Cancers.
Protocol: 001209Principal Investigator:
- Shridar Ganesan
Applicable Disease Sites: Any Site -
Study Protocol Cancer in Pregnancy (CIP-study)
Protocol: 012201Principal Investigator:
- Andrew Evens
Applicable Disease Sites: Any Site
Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
Fitness-Adapted, Pembrolizumab-Based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above.
Protocol: 012203Principal Investigator:
- Andrew Evens
Applicable Disease Sites: Hodgkin's Lymphoma -
Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.
Protocol: 012302Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder.
Protocol: 012306Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma.
Protocol: 012404Principal Investigator:
- Andrew Evens
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma.
Protocol: 012405Principal Investigator:
- Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination with Other Anticancer Agents in Participants with Mature B-Cell Malignancies.
Protocol: 012408Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma.
Protocol: 012503Principal Investigator:
- Joanna Rhodes
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
A Phase 1 Open-Label, Multi-Center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT-200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/Refractory, High/Very High Risk Myelodysplastic Syndrome (MDS).
Protocol: 022204Principal Investigator:
- Dale Schaar
Applicable Disease Sites: Myeloid and Monocytic Leukemia
Other Hematopoietic -
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-Like Tyrosine Kinase Mutation (FLT3 mut+): The FRIDA Study.
Protocol: 022301Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).
Protocol: 032002Principal Investigator:
- Matthew Deek
Applicable Disease Sites: Lung -
A Randomized Phase II Trial of Adjuvant Pembrolizumab versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors between 1-4 cm.
Protocol: 032006Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
The Role of Adaptive Radiation Planning in Patients with Non-Small Cell Lung Cancer on Radiation Induced Toxicity .
Protocol: 032009Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Alternating Treatment Plans for Patients with Advanced Thoracic/HN Cancers (ATATcH).
Protocol: 032201Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer.
Protocol: 032204Applicable Disease Sites: Larynx
Lip, Oral Cavity and Pharynx